[go: up one dir, main page]

PE20020720A1 - Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa - Google Patents

Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa

Info

Publication number
PE20020720A1
PE20020720A1 PE2001001296A PE2001001296A PE20020720A1 PE 20020720 A1 PE20020720 A1 PE 20020720A1 PE 2001001296 A PE2001001296 A PE 2001001296A PE 2001001296 A PE2001001296 A PE 2001001296A PE 20020720 A1 PE20020720 A1 PE 20020720A1
Authority
PE
Peru
Prior art keywords
benzimidazole
cyane
alkyl
methyl
gabaa receptors
Prior art date
Application number
PE2001001296A
Other languages
English (en)
Inventor
Pamela Albaugh
Jun Yuan
Guolin Cai
Kevin Currie
Manuka Ghosh
Linda M Gustavson
Alan Hutchison
Kyungae Lee
Guiying Li
Spiros Liras
Nian Liu
George Luke
George Maynard
Scott Mitchell
John M Peterson
Vinod Singh
Linghong Xie
Martin Patrick Allen
Original Assignee
Neurogen Corp
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corp, Pfizer filed Critical Neurogen Corp
Publication of PE20020720A1 publication Critical patent/PE20020720A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A DERIVADOS BENZIMIDAZOL Y PIRIDILIMIDAZOL DE FORMULA I DONDE Z1 ES N, CR1; Z2 ES N, CR2; Z3 ES N, CR3; Z4 ES N, CR4 CON LA CONDICION DE QUE NO MAS DE DOS Z1, Z2, Z3, Z4 SON N; R1, R2, R3 Y R4 SON H, HALOGENO, HIDROXI, NITRO, CIANO, AMINO, HALOALQUILO, HALOALCOXI, ALQUILO, CICLOALQUILO, ENTRE OTROS; R5 ES H, HALOALQUILO, ALQUILO, CICLOALQUILO, ENTRE OTROS; Q ES -C(R6)(R7), O; R6 Y R7 SON H, F, ALQUILO; X1 Y X2 SON N, C, CH; Y ES N, O, C, ENTRE OTROS; W ES ARILO, HETEROARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 1-PROPIL-2-{[2-(2-FLUORPIRID-6-IL)-1H-IMIDAZOL-1-METIL}-5-CIANO-1H-BENCIMIDAZOL, 1-ETIL-2-{[2-(3-FLUORFENIL)-PIRAZOL-3-IL]METIL}-5-CIANO-1H-BENCIMIDAZOL,1-ETIL-2-{[1-(3-FLUORFENIL)-1,2,4-TRIAZOL-5-IL]METIL}-5-CIANO-1H-BENCIMIDAZOL, ENTRE OTROS. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS. LOS COMPUESTOS MENCIONADOS PRESENTAN ALTA SELECTIVIDAD Y AFINIDAD POR LOS RECEPTORES GABAA Y SON UTILES PARA EL TRATAMIENTO DE DESORDENES DEL SISTEMA NERVIOSO CENTRAL
PE2001001296A 2000-12-21 2001-12-21 Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa PE20020720A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25749200P 2000-12-21 2000-12-21

Publications (1)

Publication Number Publication Date
PE20020720A1 true PE20020720A1 (es) 2002-08-12

Family

ID=22976520

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001296A PE20020720A1 (es) 2000-12-21 2001-12-21 Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa

Country Status (40)

Country Link
US (4) US6916819B2 (es)
EP (1) EP1368342B3 (es)
JP (1) JP2004536782A (es)
KR (1) KR100854174B1 (es)
CN (1) CN1553909A (es)
AP (1) AP1503A (es)
AR (1) AR035774A1 (es)
AT (1) ATE304008T1 (es)
AU (2) AU2002232768B2 (es)
BG (1) BG107899A (es)
BR (1) BR0116385A (es)
CA (1) CA2431592A1 (es)
CO (1) CO5390086A1 (es)
CZ (1) CZ20031676A3 (es)
DE (1) DE60113302T2 (es)
EA (1) EA007157B1 (es)
EC (1) ECSP034656A (es)
EE (1) EE05108B1 (es)
EG (1) EG24590A (es)
ES (1) ES2256325T3 (es)
HR (1) HRP20030483A9 (es)
HU (1) HUP0303849A3 (es)
IL (1) IL156294A0 (es)
IS (1) IS6855A (es)
MA (1) MA26974A1 (es)
MX (1) MXPA03005493A (es)
MY (1) MY141733A (es)
NO (1) NO326558B1 (es)
NZ (1) NZ526330A (es)
OA (1) OA12539A (es)
PA (1) PA8535601A1 (es)
PE (1) PE20020720A1 (es)
PL (1) PL366243A1 (es)
SK (1) SK7672003A3 (es)
TW (1) TWI304402B (es)
UA (1) UA75902C2 (es)
UY (1) UY27095A1 (es)
WO (1) WO2002050062A2 (es)
YU (1) YU51703A (es)
ZA (1) ZA200304544B (es)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI248936B (en) * 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
IL159811A0 (en) * 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
JP2005532991A (ja) 2002-01-10 2005-11-04 ニューロジェン・コーポレーション メラニン凝集ホルモン受容体リガンド：置換２−（４−ベンジル−ピペラジン−１−イルメチル）−及び２−（４−ベンジル−ジアゼパン−１−イルメチル）−１ｈ−ベンゾイミダゾールアナログ
US6906075B2 (en) 2002-01-10 2005-06-14 Neurogen Corp. Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
EP1499608A1 (en) * 2002-05-02 2005-01-26 Neurogen Corporation Substituted imidazole derivatives: gaba a receptor ligands
CA2484936A1 (en) * 2002-05-08 2004-05-21 Neurogen Corporation Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands
EP1506194B1 (en) * 2002-05-17 2006-07-19 Neurogen Corporation SUBSTITUTED RING-FUSED IMIDAZOLE DERIVATES: GABA sb A /sb RECEPTOR LIGANDS
US20040063938A1 (en) * 2002-09-30 2004-04-01 Pfizer Inc Process for preparing haloalkyl pyrimidines
CN100579579C (zh) * 2002-10-01 2010-01-13 诺华疫苗和诊断公司 抗癌及抗感染性疾病组合物及其使用方法
ATE335732T1 (de) * 2002-11-08 2006-09-15 Neurogen Corp 4-imidazol-1-ylmethylpyrimidinderivate als liganden für gabaa-rezeptoren
WO2004054515A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1608628A2 (en) * 2003-03-17 2005-12-28 Takeda San Diego, Inc. Histone deacetylase inhibitors
SE0301699D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ZA200600037B (en) * 2003-07-25 2007-04-25 Neurogen Corp Imidazo-pyrimidines and triazolo-pyrimidines: Benzodiazepine receptor ligands
US7271170B2 (en) 2003-07-25 2007-09-18 Neurogen Corporation Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
EP1880998A1 (en) * 2003-07-25 2008-01-23 Neurogen Corporation Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
US7781595B2 (en) 2003-09-22 2010-08-24 S*Bio Pte Ltd. Benzimidazole derivatives: preparation and pharmaceutical applications
HUP0304101A3 (en) * 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
WO2005121132A1 (ja) * 2004-06-11 2005-12-22 Shionogi & Co., Ltd. 抗ｈｃｖ作用を有する縮合ヘテロ環化合物
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
CA2625301A1 (en) * 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
EP1968972B1 (en) 2005-12-23 2012-11-28 F. Hoffmann-La Roche AG Aryl-isoxazolo-4-yl-oxadiazole derivatives
WO2007074078A2 (en) 2005-12-27 2007-07-05 F. Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazole derivatives
AU2007207053B2 (en) 2006-01-17 2012-05-24 F. Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of Alzheimer's disease via GABA receptors
AU2007267183B2 (en) 2006-05-31 2011-10-20 F. Hoffmann-La Roche Ag Aryl-4-ethynyl-isoxazole derivatives
TW200808772A (en) * 2006-06-13 2008-02-16 Astrazeneca Ab Therapeutic compounds
US8492378B2 (en) 2006-08-03 2013-07-23 Takeda Pharmaceutical Company Limited GSK-3β inhibitor
EP2088861A4 (en) * 2006-10-25 2010-07-07 Takeda Pharmaceutical Benzimidazole compounds
AU2008267894B2 (en) 2007-06-22 2012-08-23 F. Hoffmann-La Roche Ag Isoxazole-imidazole derivatives
TW200911803A (en) * 2007-07-16 2009-03-16 Organon Nv 6-phenyl-1H-imidazo [4,5-c] pyridine-4-carbonitrile derivatives
CA2702292A1 (en) * 2007-08-10 2009-02-19 Rudolf Mueller Bicyclic amides for ehancing glutamatergic synaptic responses
US7902201B2 (en) 2007-12-04 2011-03-08 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
CA2706990C (en) 2007-12-04 2016-05-10 F. Hoffmann-La Roche Ag Isoxazolo-pyrazine derivatives
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
TW201033201A (en) 2009-02-19 2010-09-16 Hoffmann La Roche Isoxazole-isoxazole and isoxazole-isothiazole derivatives
US8389550B2 (en) 2009-02-25 2013-03-05 Hoffmann-La Roche Inc. Isoxazoles / O-pyridines with ethyl and ethenyl linker
US8222246B2 (en) 2009-04-02 2012-07-17 Hoffmann-La Roche Inc. Substituted isoxazoles
US20100280019A1 (en) 2009-04-30 2010-11-04 Roland Jakob-Roetne Isoxazoles
SG175780A1 (en) 2009-05-05 2011-12-29 Hoffmann La Roche Isoxazole-pyridazine derivatives
AU2010244553A1 (en) 2009-05-05 2011-12-01 F. Hoffmann-La Roche Ag Isoxazole-pyridine derivatives
MX2011011273A (es) 2009-05-05 2011-11-04 Hoffmann La Roche Derivados de isoxazol-pirazol.
CA2759598C (en) 2009-05-05 2017-09-12 F. Hoffmann-La Roche Ag Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
ES2430223T3 (es) 2009-05-07 2013-11-19 F. Hoffmann-La Roche Ag Derivados de isoxazol-piridina como moduladores de GABA
RU2635662C2 (ru) * 2010-09-10 2017-11-15 Сионоги Энд Ко., Лтд. Конденсированное с гетерокольцом имидазольное производное, обладающее активирующим амрк действием
PT2624696T (pt) 2010-10-06 2017-03-21 Glaxosmithkline Llc Derivados de benzimidazole como inibidores da cinase pi3
DK3034079T3 (en) 2010-11-15 2018-02-05 Agenebio Inc PYRIDAZINE DERIVATIVES, COMPOSITIONS AND PROCEDURES FOR TREATING COGNITIVE WEAKNESS
SG192941A1 (en) * 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140187533A1 (en) 2011-03-03 2014-07-03 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
CN102653531B (zh) * 2011-03-04 2014-08-13 上海爱普植物科技有限公司 一种马索亚内酯的合成方法
WO2013021044A1 (de) * 2011-08-11 2013-02-14 Bayer Intellectual Property Gmbh 1,2,4-triazolyl-substituierte ketoenole
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
GB201119538D0 (en) * 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
JP6126626B2 (ja) 2012-01-11 2017-05-10 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ テトラゾール−５−イル−およびトリアゾール−５−イル−アリール化合物ならびに除草剤としてのそれの使用
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CA2875990A1 (en) 2012-05-24 2013-11-28 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
JP6230344B2 (ja) * 2013-09-06 2017-11-15 株式会社東芝 蒸気タービンプラント
WO2015052173A1 (en) 2013-10-10 2015-04-16 Basf Se Tetrazole and triazole compounds and their use as herbicides
WO2015052178A1 (en) 2013-10-10 2015-04-16 Basf Se 1,2,5-oxadiazole compounds and their use as herbicides
CA3123897C (en) 2013-12-20 2024-02-06 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3099672A4 (en) * 2014-01-31 2017-09-20 ONO Pharmaceutical Co., Ltd. Fused imidazole compounds
WO2015121136A1 (de) * 2014-02-17 2015-08-20 Bayer Cropscience Ag 2-(het)aryl-substituierte kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
AU2015295248B2 (en) * 2014-07-31 2019-05-16 Institut Pasteur Korea 2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin e synthase inhibitors
EP3954685B1 (en) 2014-12-29 2025-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
UY36547A (es) 2015-02-05 2016-06-01 Bayer Cropscience Ag Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas
UY36548A (es) 2015-02-05 2016-06-01 Bayer Cropscience Ag Derivados heterocíclicos condensados bicíclicos sustituidos por 2-(het)arilo como pesticidas
US10188108B2 (en) 2015-04-08 2019-01-29 Bayer Cropscience Aktiengesellschaft Fused bicyclic heterocycle derivatives as pesticides
CN108026107B (zh) 2015-06-19 2021-07-30 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
RU2748884C2 (ru) 2015-07-20 2021-06-01 Джензим Корпорейшн Ингибиторы рецептора колониестимулирующего фактора-1 (csf-1r)
JP6913076B2 (ja) 2015-08-07 2021-08-04 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 有害生物防除剤としての２−（ヘタ）アリール−置換縮合ヘテロ環誘導体
RU2018119344A (ru) 2015-10-26 2019-11-28 Байер Кропсайенс Акциенгезельшафт Конденсированные бициклические гетероциклические производные в качестве средства для борьбы с вредителями
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2017144341A1 (de) 2016-02-23 2017-08-31 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
WO2017157332A1 (zh) * 2016-03-18 2017-09-21 江苏恒瑞医药股份有限公司 芳香酰胺类衍生物、其制备方法及其在医药上的应用
WO2017174414A1 (de) 2016-04-05 2017-10-12 Bayer Cropscience Aktiengesellschaft Naphthalin-derivate als schädlingsbekämpfungsmittel
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
EP3241830A1 (de) 2016-05-04 2017-11-08 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
BR112019001135B1 (pt) 2016-07-19 2022-11-01 Bayer Cropscience Aktiengesellschaft Derivados de heterociclo bicíclico fundido como pesticidas, seu uso, formulação agroquímica, e método para controlar pragas animais
MA45918A (fr) 2016-08-15 2019-06-19 Bayer Ag Dérivés hétérocycliques bicycliques condensés utilisés comme pesticides
JP7098600B2 (ja) 2016-08-16 2022-07-11 バイエル・クロップサイエンス・アクチェンゲゼルシャフト ３Ｈ－イミダゾール［４，５－ｃ］ピリジン誘導体を有機金属亜鉛－アミン塩基と反応させることによる２－（３，６－ジハロピリジン－２－イル）－３Ｈ－イミダゾール［４，５－ｃ］ピリジン誘導体及び関連化合物の製造方法
CN109963860A (zh) 2016-09-19 2019-07-02 拜耳作物科学股份公司 吡唑并[1,5-a]吡啶衍生物及其作为农药的用途
EP3523299B1 (de) 2016-10-06 2021-04-14 Bayer CropScience Aktiengesellschaft 2-(het)aryl-substituierte kondensierte bicyclische heterocyclen-derivate als schädlings-bekämpfungsmittel
WO2018099812A1 (en) 2016-12-01 2018-06-07 Syngenta Participations Ag Pesticidally active heterocyclic derivatives with sulfur containing substituents
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
TW201833107A (zh) 2017-02-06 2018-09-16 德商拜耳廠股份有限公司 作為殺蟲劑之經２－（雜）芳基取代的稠合雜環衍生物
CN110582503B (zh) 2017-04-24 2022-05-31 拜耳公司 作为有害物防治剂的稠合双环杂环化合物衍生物
KR102622644B1 (ko) 2017-10-04 2024-01-10 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로시클릭 화합물의 유도체
EP3305786A3 (de) 2018-01-22 2018-07-25 Bayer CropScience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
EP3755700B1 (de) 2018-02-21 2021-11-24 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
JP2021522182A (ja) 2018-04-20 2021-08-30 バイエル・アクチエンゲゼルシヤフト 殺有害生物剤としてのヘテロシクレン誘導体
WO2019246300A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2020011086A1 (zh) * 2018-07-13 2020-01-16 四川科伦博泰生物医药股份有限公司 苯并二氮杂环类化合物、其制备方法及用途
EP3636645A1 (de) 2018-10-11 2020-04-15 Bayer Aktiengesellschaft Verfahren zur herstellung schwefel-substituierter pyridinderivate
MX2021010217A (es) 2019-02-26 2021-09-21 Bayer Ag Derivados heterociclos biciclicos condensados como plaguicida.
BR112021010430A2 (pt) 2019-02-26 2021-08-24 Bayer Aktiengesellschaft Derivados de heterociclo bicíclico fundido como pesticidas
AR119140A1 (es) 2019-06-13 2021-11-24 Pi Industries Ltd Compuestos heterocíclicos fusionados y su uso como agentes de control de plagas
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
CN111072681B (zh) * 2019-12-11 2020-11-06 郑州大学 一种靶向细胞膜表面gaba受体荧光探针及其制备方法和应用
JP2024500919A (ja) 2020-12-23 2024-01-10 ジェンザイム・コーポレーション 重水素化コロニー刺激因子－１受容体（ｃｓｆ－１ｒ）阻害剤
US20240132513A1 (en) 2022-08-19 2024-04-25 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
CN115490646A (zh) * 2022-10-10 2022-12-20 安徽昊帆生物有限公司 3-硝基-1，2，4-三氮唑的制备方法
CN117486846B (zh) * 2023-10-31 2025-10-03 陕西科技大学 一种卡瓦内酯类化合物的全合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3150486A1 (de) 1981-12-19 1983-08-25 Merck Patent Gmbh, 6100 Darmstadt Imidazo(4,5-c)pyridine, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
DE69617665T2 (de) * 1995-04-21 2002-05-08 Neurosearch A/S, Ballerup Benzmidazolverbindungen und ihre verwendung als modulatoren des gabaa-rezeptor-komplexes
GB9702524D0 (en) * 1997-02-07 1997-03-26 Merck Sharp & Dohme Therapeutic agents
EP1011477A1 (en) 1997-03-04 2000-06-28 Medtronic Inc. Bioprothesis film strip for surgical stapler and method of attaching the same
JP2003528802A (ja) 1999-04-02 2003-09-30 ニューロゲン コーポレイション Ｎ−ベンゾイミダゾリルメチル−及びｎ−インドリルメチル−ベンズアミド並びにｃｒｆ調節物質としてのそれらの使用
CA2369544A1 (en) 1999-04-02 2000-10-12 Robert W. Desimone Aryl and heteroaryl fused aminoalkyl-imidazole derivatives:selective modulators of bradykinin b2 receptors
EP1165519A1 (en) 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
MXPA01009949A (es) 1999-04-02 2003-07-14 Neurogen Corp Derivados aminoalquil-imidazol arilo y heteroarilo fusionados, moduladores selectivos de los receptores gaba a.
AU4218200A (en) * 1999-04-08 2000-10-23 University Of North Carolina At Chapel Hill, The Polymerization of non-fluorinated monomers in carbon dioxide
RU2243226C2 (ru) * 1999-06-22 2004-12-27 НьюроСёрч А/С Новые производные бензимидазола и содержащие эти соединения фармацевтические композиции
GB9921150D0 (en) * 1999-09-07 1999-11-10 Merck Sharp & Dohme Therapeutic agents
YU23503A (sh) 2000-09-29 2006-03-03 Neurogen Corporation Mali molekuli kao modulatori receptora c5a visokog afiniteta
MXPA03003039A (es) 2000-10-06 2003-10-15 Neurogen Corp Derivados de indola y bencimidazola como moduladores del receptor crf.
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof

Also Published As

Publication number Publication date
MY141733A (en) 2010-06-15
AP2003002818A0 (en) 2003-06-30
NO20032834D0 (no) 2003-06-20
JP2004536782A (ja) 2004-12-09
US7300945B2 (en) 2007-11-27
EE200300304A (et) 2003-12-15
HRP20030483A9 (en) 2007-11-30
KR100854174B1 (ko) 2008-08-26
PA8535601A1 (es) 2002-11-28
NO20032834L (no) 2003-08-08
OA12539A (en) 2006-06-05
EA007157B1 (ru) 2006-08-25
SK7672003A3 (en) 2004-07-07
EA200300713A1 (ru) 2004-02-26
ATE304008T1 (de) 2005-09-15
MA26974A1 (fr) 2004-12-20
IL156294A0 (en) 2004-01-04
EP1368342B3 (en) 2010-12-01
US20060025425A1 (en) 2006-02-02
ZA200304544B (en) 2005-05-25
HRP20030483A2 (en) 2005-04-30
AU2002232768B2 (en) 2007-09-06
EP1368342B1 (en) 2005-09-07
PL366243A1 (en) 2005-01-24
IS6855A (is) 2003-06-20
ES2256325T3 (es) 2006-07-16
US7642267B2 (en) 2010-01-05
US20100267698A1 (en) 2010-10-21
NZ526330A (en) 2006-09-29
NO326558B1 (no) 2009-01-12
CA2431592A1 (en) 2002-06-27
HUP0303849A3 (en) 2009-08-28
CZ20031676A3 (en) 2004-03-17
US6916819B2 (en) 2005-07-12
CN1553909A (zh) 2004-12-08
BG107899A (bg) 2004-08-31
KR20030071789A (ko) 2003-09-06
US20030069257A1 (en) 2003-04-10
EE05108B1 (et) 2008-12-15
UY27095A1 (es) 2002-07-31
ECSP034656A (es) 2003-10-28
AR035774A1 (es) 2004-07-14
AU3276802A (en) 2002-07-01
AP1503A (en) 2005-12-24
WO2002050062A3 (en) 2003-01-16
US20080227793A1 (en) 2008-09-18
EP1368342A2 (en) 2003-12-10
DE60113302T2 (de) 2006-06-29
EG24590A (en) 2009-12-07
MXPA03005493A (es) 2004-04-20
TWI304402B (en) 2008-12-21
BR0116385A (pt) 2005-12-13
WO2002050062A2 (en) 2002-06-27
YU51703A (sh) 2006-05-25
CO5390086A1 (es) 2004-04-30
DE60113302D1 (de) 2005-10-13
UA75902C2 (en) 2006-06-15
HUP0303849A2 (hu) 2004-03-01

Similar Documents

Publication Publication Date Title
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
PE59999A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona-8-sustituidos
PE20040935A1 (es) Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
UY28150A1 (es) Agentes terapeuticos
PE20020911A1 (es) Derivados de indol como agonistas de 5ht2
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
PE20040583A1 (es) Nuevos derivados de benzimidazol
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
AR054799A1 (es) Derivados de oxindol
PE20020589A1 (es) 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas
ES2113368T3 (es) Antagonistas de serotonina.
AR029215A1 (es) Derivados de benzazol y tautomeros de los mismos utiles en el tratamiento de desordenes en los sistemas de autoinmunidad y neuronales, uso de dichos derivados en la preparacion de composiciones farmaceuticas aplicables en el tratamiento de dichos desordenes, metodo prar inhibir la expresion y/o acti
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
PE20001551A1 (es) Derivados de eter biarilico como inhibidores de la recaptacion de monoaminas para el tratamiento de trastornos del snc
UY27976A1 (es) Piperazinas heterocíclicas sustituídas para el tratamiento de la esquizofrenia
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
PE20030610A1 (es) Derivados de 3-azabiciclo[3.1.0]hexano con afinidad a los receptores opioides
ES2084996T3 (es) Piperazinas sustituidas utiles como agentes para el sistema nervioso central.
ES2038707T3 (es) Procedimiento para la obtencion de enantiomeros (+) y (-) de derivados de la 3,4-dihidro-2h-(1)-benzopiran-3-amina.
PE20040763A1 (es) Derivados de aminoalcoxiindoles como ligandos de los receptores 5-ht6

Legal Events

Date Code Title Description
FC Refusal